RD140 / IASO BIO - LARVOL DELTA

First-in-Human Phase 1 Study of RD140, a Fully Human BCMA/GPRC5D Dual-Targeting FasT CAR-T, in Relapsed/Refractory Multiple Myeloma(RRMM) and Plasma Cell Leukemia(PCL) (IMS 2026) - P1 | "Following lymphodepletion with cyclophosphamide 500 mg/m2 and fludarabine 30 mg/m 2 for three consecutive days, RD140 was administered as single infusion at 2 dose levels (DL) of 1x10 5 cells/kg (DL1, n = 3) or 3x10 5 cells/kg (DL2, n=6). The current data demonstrated that BCMA/GPRC5D dual-targeting FasT CAR-T RD140 provide deep responses and a very high MRD negativity rate with a favorable safety profile, including in RRMM pts exposed to anti-CD38, PI and IMiDs. Further evaluation in a larger patient population with longer follow-up is warranted."

CAR T-Cell Therapy • First-in-human • P1 data • Hematological Disorders • Hematological Malignancies • Inflammation • Leukemia • Multiple Myeloma • Plasma Cell Leukemia

An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Peking University People's Hospital

New P1 trial • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • Plasma Cell Leukemia

First-in-Human Phase 1 Study of RD140, a Fully Human BCMA/GPRC5D Dual-Targeting FasT CAR-T, in Relapsed/Refractory Multiple Myeloma(RRMM) and Plasma Cell Leukemia(PCL) (IMS 2026) - P1 | "Following lymphodepletion with cyclophosphamide 500 mg/m2 and fludarabine 30 mg/m 2 for three consecutive days, RD140 was administered as single infusion at 2 dose levels (DL) of 1x10 5 cells/kg (DL1, n = 3) or 3x10 5 cells/kg (DL2, n=6). The current data demonstrated that BCMA/GPRC5D dual-targeting FasT CAR-T RD140 provide deep responses and a very high MRD negativity rate with a favorable safety profile, including in RRMM pts exposed to anti-CD38, PI and IMiDs. Further evaluation in a larger patient population with longer follow-up is warranted."

CAR T-Cell Therapy • First-in-human • P1 data • Hematological Disorders • Hematological Malignancies • Inflammation • Leukemia • Multiple Myeloma • Plasma Cell Leukemia

2026 IMS | IASO Bio Presents First-in-Human Phase 1 Data of RD140, a Fully Human BCMA/GPRC5D Dual-Targeted FasT CAR-T (PRNewswire) - "Poster presentation selected for the poster discussion session (Abstract No.: PA-200): in a first-in-human study in 9 heavily pretreated, high-risk patients with relapsed/refractory multiple myeloma or plasma cell leukemia, RD140, a fully human BCMA/GPRC5D dual-targeted FasT CAR-T, achieved an objective response rate (ORR) of 88.9% (100% in the higher-dose cohort) and a minimal residual disease (MRD) negativity rate of 88.9%. No neurotoxicity, including ICANS, was observed, and cytokine release syndrome was predominantly low-grade; built on the FasT CAR-T rapid manufacturing platform, RD140 completes cell manufacturing in just 3–4 days."

First-in-human • P1 data • Multiple Myeloma • Plasma Cell Leukemia